We put the AI chatbot to the test, asking if a savvy $1,000 investment in 2015 could have grown to $1 million by 2025. The answer reveals the extreme rarity of such returns in mainstream markets and highlights the stark difference between hindsight and feasible strategy.
Coinbase CEO Brian Armstrong announces the company will match the U.S. government's $1,000 'Trump Accounts' contribution for eligible children of employees, with a preference to execute the match in Bitcoin, highlighting crypto's growing intersection with federal policy initiatives.
As one of the oldest cryptocurrencies, Dogecoin faces a critical juncture. With its price down over 80% from its 2021 peak and questions about its long-term utility mounting, investors are weighing whether the iconic digital asset has a future or is fading into irrelevance.
Bitcoin's sharp retreat to $81,000 on Thursday, following the Federal Reserve's latest policy announcement, resulted in massive leveraged position liquidations and sent shockwaves through correlated equities.
A provocative art installation in Tokyo, featuring a violently thrashing robot dog restrained by a metal chain, is drawing crowds and forcing viewers to confront uneasy questions about the future of artificial intelligence, ethics, and our emotional connection to machines.
Amid a broad crypto market downturn, Bitcoin's relative resilience and long-term growth narrative make it a standout choice for investors looking to deploy a modest $500, despite the allure of riskier, high-volatility alternatives.
Summit Therapeutics (SMMT) finds itself at a crossroads, with its stock down over 30% in the past year. Conflicting signals from valuation models paint a complex picture: is the biotech firm dramatically overvalued on traditional metrics, or deeply undervalued based on future cash flows?
Nissan Motor Co. faced a 4.4% decline in global sales for 2025, with a sharper 6.7% drop in December, as weakness in key markets like China and Europe offset gains in North America.
While the crypto market navigates volatility, two assets priced under $2—XRP and Sui—are drawing institutional interest and possess specific catalysts that could drive significant growth in the coming year.
Ethereum enters February 2026 under pressure, testing key support near $2,690 after a historically weak January. Analysts are divided on whether seasonal trends or shifting on-chain dynamics will dictate the month's direction.
President Donald Trump is expected to nominate Kevin Warsh, a former Federal Reserve governor with a notably more open stance toward Bitcoin, to lead the central bank. The anticipated move has already triggered market reactions and reshaped expectations for U.S. monetary policy.
Once crypto miners, IREN and Applied Digital have pivoted to AI infrastructure, delivering staggering returns. But as valuations soar, investors face a critical choice between predictable cash flow and high-growth optionality.
A sharp downturn in Bitcoin triggered a massive $1.7 billion liquidation event over 24 hours, with leveraged long positions bearing the brunt of the sell-off as market sentiment shifted.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
Motorpoint Group, the UK's largest independent car retailer, is showing signs of strain as its return on capital employed (ROCE) has fallen significantly over the past five years. While still above the industry average, the downward trend, coupled with rising current liabilities, suggests challenges ahead for the London-listed firm.
Bitcoin's struggle to hold the $90,000 level intensifies as a massive monthly options expiry approaches, driving traders toward defensive positioning and heightened volatility hedging.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Keefe Bruyette & Woods raises its price target on Riot Platforms (RIOT) to $23, citing a new long-term agreement with AMD that provides revenue visibility and supports the company's high-performance computing strategy.
Keefe Bruyette significantly raises its price target for Cipher Mining (CIFR), citing the company's strategic expansion into AI and high-performance computing data centers as a key growth driver.
Wall Street firms Keefe Bruyette and BTIG have raised price targets on Core Scientific, citing the company's strategic shift from Bitcoin mining to high-performance computing infrastructure for AI as a key driver for future growth.
